State Of Wisconsin Investment Board I Teos Therapeutics, Inc. Transaction History

State Of Wisconsin Investment Board

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$8.57 - $11.06 $77,978 - $100,634	-9,099 Reduced 16.88%	44,804 $490,000
Q3 2023 Nov 14, 2023	SELL	$10.95 - $14.6 $121,884 - $162,512	-11,131 Reduced 17.12%	53,903 $590,000
Q2 2023 Aug 14, 2023	BUY	$12.93 - $18.05 $274,956 - $383,833	21,265 Added 48.58%	65,034 $861,000
Q1 2023 May 15, 2023	BUY	$13.02 - $22.62 $327,166 - $568,395	25,128 Added 134.8%	43,769 $595,000
Q4 2022 Feb 14, 2023	SELL	$17.77 - $21.6 $21,430 - $26,049	-1,206 Reduced 6.08%	18,641 $364,000
Q3 2022 Nov 14, 2022	BUY	$18.6 - $27.25 $64,504 - $94,503	3,468 Added 21.17%	19,847 $378,000
Q2 2022 Aug 15, 2022	SELL	$16.57 - $35.1 $174,332 - $369,287	-10,521 Reduced 39.11%	16,379 $337,000
Q4 2021 Feb 11, 2022	BUY	$26.23 - $47.86 $312,137 - $569,534	11,900 Added 79.33%	26,900 $1.25 Million
Q4 2020 Feb 03, 2021	BUY	$21.59 - $33.95 $323,850 - $509,250	15,000 New	15,000 $507,000

169

36.6M

1.95M

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $285M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

Stay updated on State Of Wisconsin Investment Board with notifications on news.